Salvage of Cardiac Implantable Electronic Device Pocket Infection with Skin Erosion in Frail 92-Year-Old

Marzia Giaccardi, Benito Baldauf, Ernest W Lau, Stefan Borov, Hendrik Bonnemeier, Marzia Giaccardi, Benito Baldauf, Ernest W Lau, Stefan Borov, Hendrik Bonnemeier

Abstract

We reported the novel use of a taurolidine-containing antimicrobial solution in the successful salvage of a partially exposed and polymicrobially infected cardiac implantable electronic device pulse generator in a frail patient unfit for lead extraction. The old, salvaged device was entirely internalized, and there were no signs of recurrent infection at 9 months follow-up.

Keywords: cardiac implantable electronic device; revision; surgical site infection; taurolidine.

Conflict of interest statement

B. Baldauf is a medical consultant for the manufacturer of TauroPace™. The other authors declare no conflict of interest in relation to this publication.

Figures

Figure 1
Figure 1
(a) Pulse generator protrusion through skin erosion (biofilm formation at the skin edges). (b) Initial elliptical incision around skin defect during salvage procedure. (c) Fibrous and subcutaneous tissues encasing the pulse generator and leads were only exposed after removal outside the patient’s body. (d) A new sub-pectoral pocket was fashioned. (e) The old pulse generator was re-attached to the old leads after ex vivo and in vivo sterilisation with TauroPace™ prior to insertion into the new sub-pectoral pocket.
Figure 2
Figure 2
(a) The skin edges were closed with interrupted sutures. (b) Skin removed and sent in for histopathology. (c) Suture fixation sleeves sent in for microbiology. (d) Fibrous lining surrounding pulse generator and leads sent in for histopathology. (e) The pocket and wound looked healthy with no sign of recurrent infection, underlying abscess formation, or skin erosion 7 days post procedure.

References

    1. Greenspon A.J., Patel J.D., Lau E., Ochoa J.A., Frisch D.R., Ho R.T., Pavri B.B., Kurtz S.M. 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States 1993 to 2008. J. Am. Coll. Cardiol. 2011;58:1001–1006. doi: 10.1016/j.jacc.2011.04.033.
    1. Sohail M.R., Eby E.L., Ryan M.P., Gunnarsson C., Wright L.A., Greenspon A.J. Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation. Circ. Arrhythm. Electrophysiol. 2016;9:e003929. doi: 10.1161/CIRCEP.116.003929.
    1. Blomström-Lundqvist C., Traykov V., Erba P.A., Burri H., Nielsen J.C., Bongiorni M.G., Poole J., Boriani G., Costa R., Deharo J.-C., et al. European Heart Rhythm Association (EHRA) International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections—Endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Europace. 2020;22:515–549. doi: 10.1093/europace/euz246.
    1. Traykov V., Bongiorni M.G., Boriani G., Burri H., Costa R., Dagres N., Deharo J.-C., Epstein L., Erba P.A., Snygg-Martin U., et al. Clinical Practice and Implementation of Guidelines for the Prevention, Diagnosis and Management of Cardiac Implantable Electronic Device Infections: Results of a Worldwide Survey under the Auspices of the European Heart Rhythm Association. Europace. 2019;21:1270–1279. doi: 10.1093/europace/euz137.
    1. DeSimone D.C., Sohail M.R., Mulpuru S.K. Contemporary Management of Cardiac Implantable Electronic Device Infection. Heart. 2019;105:961–965. doi: 10.1136/heartjnl-2017-312146.
    1. Knigina L., Kühn C., Kutschka I., Oswald H., Klein G., Haverich A., Pichlmaier M. Treatment of Patients with Recurrent or Persistent Infection of Cardiac Implantable Electronic Devices. Europace. 2010;12:1275–1281. doi: 10.1093/europace/euq192.
    1. Kusumoto F.M., Schoenfeld M.H., Wilkoff B.L., Berul C.I., Birgersdotter-Green U.M., Carrillo R., Cha Y.-M., Clancy J., Deharo J.-C., Ellenbogen K.A., et al. 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction. Heart Rhythm. 2017;14:e503–e551. doi: 10.1016/j.hrthm.2017.09.001.
    1. Schaller R.D., Cooper J.M. Salvage of Focally Infected Implantable Cardioverter-Defibrillator System by in Situ Hardware Sterilization. HeartRhythm Case Rep. 2017;3:431–435. doi: 10.1016/j.hrcr.2017.06.011.
    1. Roshdy H., Seaoud E., Elbelbesy R. Low-Budget, Single-Session Elimination of CIED Pocket Infection. Pacing Clin. Electrophysiol. 2021;44:129–134. doi: 10.1111/pace.14133.
    1. Kirsch L.E., Sihn Y.S. The Effect of Polyvinylpyrrolidine on the Stability of Taurolidine. Pharm. Dev. Technol. 1997;2:345–356. doi: 10.3109/10837459709022633.
    1. Gong L., Greenberg H.E., Perhach J.L., Waldman S., Kraft W.K. The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers. J. Clin. Pharmacol. 2007;47:697–703. doi: 10.1177/0091270007299929.
    1. Stendel R., Scheurer L., Schlatterer K., Stalder U., Pfirrmann R.W., Fiss I., Öhler H.M., Bigler L. Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma Patients. Clin. Pharmacokinet. 2007;46:513–524. doi: 10.2165/00003088-200746060-00005.
    1. William R., Watson G., Redmond H.P., Carthy J.M., Bouchier-Hayes D. Taurolidine, an Antilipopolysaccharide Agent, Has Immunoregulatory Properties That Are Mediated by the Amino Acid Taurine. J. Leukoc. Biol. 1995;58:299–306. doi: 10.1002/jlb.58.3.299.
    1. Monson J.R., Ramsey P., Donohue J.H. Taurolidine Inhibits Tumour Necrosis Factor (TNF) Toxicity—New Evidence of TNF and Endotoxin Synergy. Eur. J. Surg. Oncol. (EJSO) 1993;19:226–231.
    1. Caruso F., Darnowski J.W., Opazo C., Goldberg A., Kishore N., Agoston E.S., Rossi M. Taurolidine Antiadhesive Properties on Interaction with E. coli; Its Transformation in Biological Environment and Interaction with Bacteria Cell Wall. PLoS ONE. 2010;5:e8927. doi: 10.1371/journal.pone.0008927.
    1. Blenkharn J.I. Sustained Anti-Adherence Activity of Taurolidine (Taurolin) and Noxythiolin (Noxyflex S) Solutions. J. Pharm. Pharmacol. 1988;40:509–511. doi: 10.1111/j.2042-7158.1988.tb05288.x.
    1. Gorman S.P., McCafferty D.F., Woolfson A.D., Jones D.S. Electron and Light Microscopic Observations of Bacterial Cell Surface Effects due to Taurolidine Treatment. Lett. Appl. Microbiol. 1987;4:103–109. doi: 10.1111/j.1472-765X.1987.tb01593.x.
    1. Rafiee S., Samadnejad A.Z., Zarifi F., Asgari Q., Ashkani-Esfahani S., Noorafshan A. Taurine Improves the Wound Healing Process in Cutaneous Leishmaniasis in Mice Model, Based on Stereological Parameters. Adv. Biomed. Res. 2014;3:204. doi: 10.4103/2277-9175.142314.
    1. Dinçer S.L., Babul A., Erdogan D., Özogul C. Effect of Taurine on Wound Healing. Amino Acids. 1996;10:59–71. doi: 10.1007/BF00806093.
    1. DeĞim Z., Çelebi N., Sayan H., Babül A., Erdoğan D., Take G. An Investigation on Skin Wound Healing in Mice with a Taurine-Chitosan Gel Formulation. Amino Acids. 2002;22:187–198. doi: 10.1007/s007260200007.
    1. Kleemann T., Becker T., Strauss M., Dyck N., Weisse U., Saggau W., Burkhardt U., Seidl K. Prevalence of Bacterial Colonization of Generator Pockets in Implantable Cardioverter Defibrillator Patients without Signs of Infection Undergoing Generator Replacement or Lead Revision. Europace. 2009;12:58–63. doi: 10.1093/europace/eup334.
    1. Cassagneau R., Ploux S., Ritter P., Jan E., Barandon L., Deplagne A., Clementy J., Haïssaguerre M., Bordachar P. Long-Term Outcomes after Pocket or Scar Revision and Reimplantation of Pacemakers with Preerosion. Pacing Clin. Electrophysiol. 2010;34:150–154. doi: 10.1111/j.1540-8159.2010.02950.x.
    1. Peacock J.E., Jr., Stafford J.M., Le K., Sohail M.R., Baddour L.M., Prutkin J.M., Danik S.B., Vikram H.R., Hernandez-Meneses M., Miró J.M., et al. Attempted Salvage of Infected Cardiovascular Implantable Electronic Devices: Are There Clinical Factors That Predict Success? Pacing Clin. Electrophysiol. 2018;41:524–531. doi: 10.1111/pace.13319.
    1. Weichsel J., Baldauf B., Bonnemeier H., Lau E.W., Dittrich S., Cesnjevar R. Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine. J. Cardiovasc. Dev. Dis. 2022;9:18. doi: 10.3390/jcdd9010018.
    1. Borov S., Baldauf B., Lau E.W., Bonnemeier H. Salvage of Infected Cardiac Implantable Electronic Device with Taurolidine—A Case Report. Cardiothorac. Surg. 2022;30:1–4. doi: 10.1186/s43057-022-00068-5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir